what is glp-1 shots Why GLP‑1 users need a new kind of health tracking app GLP-1 Agonists: A Comprehensive Overview

The main ongoing studies: REDEFINE 1 , Phase 3 obesity without T2D (results 20242025, preliminarily 25.3 %) REDEFINE 2 , Phase 3 obesity + T2D REDEFINE 3 , Phase 3 cardiovascular outcome trial (n~7000) Stand-alone clinical development of Cagrilintide is limited , Novo Nordisk is primarily investing in the CagriSema combination

It works by mimicking the action of the GLP-1 hormone, which regulates appetite and food intake

Many side effects occur during the first weeks of therapy, especially while doses are being increased

Bloating or feeling overly full after small meals (delayed gastric emptying)

When the dose changes, the units change, and you need a deliberate moment of updating your routine, not hoping you remember to do more math at the right time